SEARCH

SEARCH BY CITATION

References

  • Bibl M., Esselmann H., Otto M., Lewczuk P., Cepek L., Rüther E. and Kornhuber J. (2004) Cerebrospinal fluid (CSF) amyloid beta (Aβ) peptide patterns in Alzheimer’s disease (AD) patients and non-demented controls depend on sample pre-treatment: Indication of carrier- mediated epitope masking of Aβ peptides. Electrophoresis 25, 29128.
  • Bibl M., Mollenhauer B., Esselmann H. et al. (2006) CSF amyloid-β-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Brain 129, 11771187.
  • Bibl M., Mollenhauer B., Lewczuk P. et al. (2007) Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias. Mol. Psy. 12, 671680.
  • Blennow K. (2004) Cerebrospinal Fluid Protein Biomarkers for Alzheimer’s disease. NeuroRX 1, 213225.
  • Fischer P., Jellinger K., Gatterer G. and Danielczyk W. (1991) Prospective neuropathological validation of Hachinski’s ischaemic score in dementias. J. Neurol. Neurosurg. Psychiatry 7, 580583.
  • Fukumoto H., Tennis M., Locascio J. J., Hyman B. T., Growdon J. H. and Irizarry M. C. (2003) Age but not diagnosis is the main predictor of plasma amyloid β-protein levels. Arch. Neurol. 60, 958964.
  • Gibb W. R. and Lees A. J. (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 51, 745752.
  • Gravina S. A., Ho L., Eckman C. B., Long K. E., Otvos L. Jr, Younkin L. H., Suzuki N. and Younkin S. G. (1995) Amyloid β protein in Alzheimer’s diesease brain. J. Biol. Chem. 270, 70137016.
  • Güntert A., Döbeli H. and Bohrmann B. (2006) High sensitivity analysis of Amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 143, 461475.
  • Gurol M. E., Irizarry M. C., Smith E. E., Raju S., Diaz-Arrastia R., Bottiglieri T., Rosand J., Growdon J. H. and Greenberg S. M. (2006) Plasma β-amyloid and white matter lesions in AD, MCI and cerebral amyloid angiopathy. Neurology 66, 2329.
  • Hulstaert F., Blennow K., Ivanoiu A. et al. (1999) Improved discrimination of AD-patients using ß-amyloid (1–42) and tau levels in CSF. Neurology 52, 15551562.
  • Irizarry M. C. (2004) Biomarkers of Alzheimer disease in plasma. NeuroRX 1, 226234.
  • Janek K., Rothemund S., Gast K., Beyermann M., Zipper J., Fabian H., Bienert M. and Krause E. (2001) Study of the conformational transition of A beta(1–42) using D-amino acid replacement analogues. Biochemistry 40, 54575463.
  • Lewczuk P., Esselmann H., Bibl M. et al. (2004) Electrophoretic separation of amyloid β (Aβ) peptides in plasma. Electrophoresis 25, 33363343.
  • Loeb C. and Meyer J. S. (1996) Vascular dementia: still a debatable entity?. J. Neurol. Sci. 143, 3140.
  • McKeith I. G., Galasko D., Kosaka K. et al. (1996) Consensus guidlines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47, 11131124.
  • McKhann G., Drachman D., Folstein M., Katzmann R., Price D. and Stadlan E. M. (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34, 939944.
  • Mehta P. D. and Pirttila T. (2005) Increased cerebrospinal fluid A bata38/A beta42 in Alzheimer disease. Neurodegener. Dis. 2, 242245.
  • Mollenhauer B., Cepek L., Bibl M. et al. (2006) Aβ1–42 and tau protein in cerebrospinal fluid of patients with Parkinson’s disease dementia. Dement. Geriatr. Cogn. Disord. 22, 200208.
  • O’Brien J. T., Erkinjutti T., Reisberg B. et al. (2003) Vascular cognitive impairment. Lancet Neurol. 2, 8997.
  • Pomara N., Doraiswamy P. M., Willoughby L. M., Roth A. E., Mulsant B. H., Sidtis J. J., Mehta P. D., Reynolds C. F. and Pollock B. G. (2006) Elevation in plasma Abeta42 in geriatric depression: a pilot study. Neurochem. Res. 31, 341349.
  • Roman G. C., Tatemichi T. K., Erkinjutti T., Cummings J. L., Masdeu J. C., Garcia J. H., Amaducci L., Orgogozo J. M., Brun A. and Hofmann A. (1993) Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 43, 243245.
  • Schoonenboom N. S., Mulder C., Van Kamp G. J., Mehta S. P., Scheltens P., Blankenstein M. A. and Mehta P. D. (2005) Amyloid β 38, 40 and 42 species in cerebrospinal fluid: More of the same?. Ann. Neurol. 58, 139142.
  • Van Oijen M., Hofmann A., Soares H. D., Koudstaal P. J. and Breeteler M. M. B. (2006) Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 5, 655660.
  • Weggen S., Eriksen J. L., Das P. et al. (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212216.
  • Wiltfang J., Esselmann H., Cupers P. et al. (2001) Elevation of β-amyloid peptide 2–42 in sporadic and familial Alzheimer’s Disease and its generation in PS1 knockout cells. J. Biol. Chem. 276, 42674542657.
  • Wiltfang J., Esselmann H., Bibl M. et al. (2002) Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer’s disease and patients with chronic neuroinflammation. J. Neurochem. 81, 481496.
  • Wiltfang J., Esselmann H., Bibl M. et al. (2007) Amyloid beta peptide ratio 42/40 but not Abeta42 corelates with phospho-Tau in patients with low- and high CSF-Abeta40 load. J. Neurochem. 101, 10531059.
  • World Medical Organisation. (1996) Declaration of Helsinki. Br. Med. J. 313, 14481449.
  • Yoshimoto M., Iwai A., Kang D., Otero D. A., Xia Y. and Saitoh T. (1995) NACP, the precursor of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Proc. Natl Acad. Sci. USA 92, 91419145.